Treating headache comprising administering an antibody to calcitonin gene-related peptide
AssigneeTeva Pharmaceuticals International GmbH
InventorsMarcelo Bigal, Sarah Walter, Henry Stern, Michael Chang
Life of this patent
Estimating the term…
Abstract
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Claims23
A method of treating or reducing incidence of headache in a subject comprising administering to the subject a dose once every three months of a monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) pathway, wherein the dose administered every three months is between 100-2000 mg, and wherein the monoclonal antibody comprises a CDR H1 as set forth in SEQ ID NO:
- 3;
- a CDR H2 as set forth in SEQ ID NO:
- 4;
- a CDR H3 as set forth in SEQ ID NO:
- 5;
- a CDR L1 as set forth in SEQ ID NO:
- 6;
- a CDR L2 as set forth in SEQ ID NO:
- 7;
- and a CDR L3 as set forth in SEQ ID NO:
- 8.
A method of treating or reducing incidence of headache in a subject comprising administering to the subject a 675 mg dose of a monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) pathway once every three months;
- wherein the monoclonal antibody comprises a CDR H1 as set forth in SEQ ID NO:
- 3;
- a CDR H2 as set forth in SEQ ID NO:
- 4;
- a CDR H3 as set forth in SEQ ID NO:
- 5;
- a CDR L1 as set forth in SEQ ID NO:
- 6;
- a CDR L2 as set forth in SEQ ID NO:
- 7;
- and a CDR L3 as set forth in SEQ ID NO:
- 8;
- and
- wherein the 675 mg dose is administered as three consecutive 225 mg subcutaneous injections of 1.5 mL to the abdomen, thigh, or upper arm of the subject's body.
Dependencies are inferred from the claim text.